US equities
|
NVDA
$186.64
▲+2.78%
MU
$690.00
▲+5.12%
AMD
$449.04
▲+11.04%
SPCX
$134.27
▲+8.62%
AAPL
$342.37
▼-0.52%
SNDK
$835.06
▲+3.55%
MSFT
$530.61
▼-0.99%
TSLA
$358.22
▲+4.23%
NVDA
$186.64
▲+2.78%
MU
$690.00
▲+5.12%
AMD
$449.04
▲+11.04%
SPCX
$134.27
▲+8.62%
AAPL
$342.37
▼-0.52%
SNDK
$835.06
▲+3.55%
MSFT
$530.61
▼-0.99%
TSLA
$358.22
▲+4.23%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Evommune, Inc.
Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
November 05, 2026
From
Evommune, Inc.
Via
Business Wire
Tickers
EVMN
Evommune Announces $30 Million Private Placement
November 04, 2026
From
Evommune, Inc.
Via
Business Wire
Tickers
EVMN
Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals
November 04, 2026
From
Evommune, Inc.
Via
Business Wire
Tickers
EVMN
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
October 01, 2026
From
Evommune, Inc.
Via
Business Wire
Tickers
EVMN
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
September 23, 2026
From
Evommune, Inc.
Via
Business Wire
Tickers
EVMN
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
September 08, 2026
From
Evommune, Inc.
Via
Business Wire
Tickers
EVMN
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
August 06, 2026
From
Evommune, Inc.
Via
Business Wire
Tickers
EVMN
Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
July 30, 2026
From
Evommune, Inc.
Via
Business Wire
Tickers
EVMN
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
June 29, 2026
From
Evommune, Inc.
Via
Business Wire
Tickers
EVMN
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
May 07, 2026
From
Evommune, Inc.
Via
Business Wire
Tickers
EVMN
Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine
April 06, 2026
From
Evommune, Inc.
Via
Business Wire
Tickers
EVMN
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
March 05, 2026
From
Evommune, Inc.
Via
Business Wire
Tickers
EVMN
Evommune Announces $125 Million Private Placement
February 12, 2026
From
Evommune, Inc.
Via
Business Wire
Tickers
EVMN
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
February 10, 2026
From
Evommune, Inc.
Via
Business Wire
Tickers
EVMN
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update
December 11, 2025
From
Evommune, Inc.
Via
Business Wire
Tickers
EVMN
